When was hpv vaccine introduced in india

Overview

The human papillomavirus (HPV) vaccine was first introduced in India in 2008, initially accessible only through private healthcare providers. It was not part of the national immunization program at the time, limiting access to those who could afford it.

Over the next decade, advocacy and clinical studies demonstrated the vaccine’s safety and effectiveness in reducing cervical cancer risk. This led to policy changes, culminating in India’s decision to integrate the HPV vaccine into its public health system.

• Introduction in 2008: The vaccine became available in private hospitals and clinics starting in 2008, primarily targeting urban, high-income families.
• Initial vaccines used: GlaxoSmithKline’s Cervarix and Merck’s Gardasil were the two main vaccines introduced, protecting against HPV types 16 and 18.
• Public sector delay: Despite early availability, the public rollout was delayed due to cost concerns, vaccine hesitancy, and ethical debates around adolescent vaccination.
• Pilot programs: Between 2016 and 2021, states like Delhi, Andhra Pradesh, and Gujarat conducted pilot HPV vaccination programs to assess feasibility and acceptance.
• National launch: The Indian government officially launched the nationwide HPV vaccination program in April 2023 under the Universal Immunization Programme (UIP).

How It Works

The HPV vaccine prevents infection from high-risk strains of the human papillomavirus, which can lead to cervical, anal, and oropharyngeal cancers. It is most effective when administered before exposure to the virus, typically in early adolescence.

• Virus type:HPV is a group of over 200 related viruses, with types 16 and 18 causing approximately 70% of cervical cancer cases globally.
• Vaccine mechanism: The vaccine uses virus-like particles (VLPs) that mimic HPV to trigger an immune response without causing infection.
• Dosing schedule: The standard regimen is two doses for girls aged 9–14, given 6 months apart, as recommended by WHO.
• Efficacy rate: Clinical trials show the vaccine is over 95% effective in preventing persistent infection with HPV types 16 and 18.
• Duration of protection: Studies indicate protection lasts at least 10 years, with no evidence of waning immunity.
• Age group: The Indian program targets girls aged 9–14 years, aligning with global best practices for maximum protection.

Comparison at a Glance

Here’s how India’s HPV vaccine rollout compares to other countries in terms of timing, coverage, and strategy.

This comparison shows India adopted the vaccine later in the public system compared to high-income countries. However, the 2023 launch aligns India with global efforts to eliminate cervical cancer, especially after WHO’s 2020 call for 90% vaccination coverage among girls by 2030.

Why It Matters

Introducing the HPV vaccine into India’s public health system is a critical step toward reducing the country’s high burden of cervical cancer, which accounts for nearly one-third of global deaths from the disease.

• High mortality rate: Over 70,000 women die annually from cervical cancer in India, making it the second most common cancer among Indian women.
• Preventable disease: Cervical cancer is largely preventable through vaccination, screening, and early treatment, yet access remains limited in rural areas.
• Cost-effective intervention: Studies estimate the HPV vaccine could prevent up to 1.3 million deaths in India over the next 50 years.
• Gender equity: Focusing on girls aged 9–14 ensures early protection, though future inclusion of boys could further reduce transmission.
• Public health integration: Adding HPV vaccine to the UIP improves equity by making it accessible to low-income and marginalized communities.
• Global goals: The rollout supports India’s commitment to the WHO’s 90-70-90 strategy to eliminate cervical cancer by 2030.

With sustained implementation and community engagement, the HPV vaccine has the potential to transform women’s health outcomes across India, significantly reducing cancer incidence and saving hundreds of thousands of lives in the coming decades.